Administrative Core

行政核心

• 批准号: 10261953
• 负责人: Monica Kraft
• 金额: $ 14.68万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-06-01 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10261953
• 关键词: 2019-nCoV; Adherence; Advisory Committees; Allergic Disease; Anions; Arizona; Asthma; Attenuated; Biological; Biological Response Modifiers; Collaborations; Collection; Communication; Communities; Data; Data Analyses; Ensure; Ethics; Fostering; Funding Opportunities; Future; Grant; Guidelines; Health; Human Resources; Immune; Immune response; Immunologic Factors; Immunomodulators; Infection; Inflammation; Inflammatory Response; Influenza A virus; Information Dissemination; Infrastructure; Institution; Lipids; Mediator of activation protein; Medical center; Molecular; Monitor; Natural Immunity; Participant; Performance; Phosphatidylglycerols; Phosphatidylinositols; Program Reviews; Publications; Pulmonary Surfactant-Associated Protein A; Recording of previous events; Regulation; Research; Research Activity; Research Personnel; Resources; Role; Sampling; Schedule; Shipping; TOLLIP gene; Time; Translating; Travel; United States National Institutes of Health; Universities; Vertebrates; Viral; Virus Diseases; Vision; Work; asthma exacerbation; base; clinical practice; conflict resolution; cost; data management; follower of religion Jewish; human subject; innate immune mechanisms; meetings; member; novel therapeutics; operation; programs; success; surfactant; symposium; synergism

This U19 Asthma and Allergic Diseases Cooperative Research Center (AACDRC) Program brings together a team of investigators in three interactive projects and two cores to focus on the pathobiology of specific innate immune mechanisms in viral infection and asthma. In the renewal of our AADCRC program, we will continue to focus on the critical and often understudied innate immune factors surfactant protein-A (SP-A), the anion lipids of surfactant, (palmitoyl-oleoyl-phosphatidylglycerol (POPG) and phosphatidylinositol (PI)) and Toll interacting protein (Tollip), an innate immune mediator known to cross talk with SP-A and the anionic lipids. Each of these mediators works synergistically to modulate inflammatory and immunologic responses in asthma and infection given their complementary functions. Our exciting preliminary data underpin our program’s overall hypothesis that POPG/PI, Tollip and SP-A function as unique immune modulators that attenuate the impact of specific viral infections (RV-C, Influenza A and SARS-CoV-2) in type-2 asthma. The investigators in this program have a long history of collaboration at the. University of Arizona and National Jewish Health; Cedar Sinai Medical Center is now included in this renewal. The Administrative Core (Core A) of this Program will perform an important role to maintain productive and vibrant collaboration, ensure and track adherence to NIH and other relevant regulations and guidelines, and manage activities that will continue to strengthen the research community surrounding this Program. The Administrative Core has the following Specific Aims: (1) Manage the day-to-day administrative details and programmatic needs of the AADCRC program by providing fiscal management, administering subcontracts, assuring that regulatory requirements in are met, and monitoring of progress with program objectives; (2) Create an infrastructure to facilitate communication between the projects, cores and. investigators, and NIH Program Directors and to provide conflict resolution should it be necessary; (3) Assist with dissemination of research findings in a timely fashion to the scientific community, both locally and nationally, and provide information to the public, including study participants; 4) Implement the Infrastructure and Opportunity Fund for the AADCRC. Our proposal builds upon our active and productive collaborations of over 20 years and will significantly enhance our understanding of the innate molecular mechanisms underlying the interaction between type 2 inflammation in and viral exacerbations of asthma. The strong synergy among our projects will accelerate progress toward novel therapies by demonstrating that the innate immune components under study protect against viral infection in asthma.

该U19哮喘和过敏性疾病合作研究中心（AACDRC）计划将 调查员团队在三个互动项目和两个核心中，专注于特定先天生物学的病理学 病毒感染和哮喘中的免疫机制。在续签我们的AADCRC计划中，我们将继续 专注于关键且经常理解的先天免疫因子表面活性剂蛋白A（SP-A）， 表面活性剂的阴离子脂质（Palmitoyl-烯酰基磷脂酰甘油（POPG）和磷脂酰肌醇（PI）） 和Toll相互作用的蛋白质（Tollip），这是一种先天免疫介质，已知与SP-A进行交谈和 阴离子脂质。这些介体中的每一个协同作用以调节炎症和免疫学 鉴于其完整功能，哮喘和感染的反应。我们令人兴奋的初步数据基础 我们计划的总体假设，即POPG/PI，Tollip和SP-A充当独特的免疫调节剂 这会衰减特定病毒感染（RV-C，流感和SARS-COV-2）的影响 哮喘。该计划中的调查人员在协作中有悠久的合作历史。亚利桑那大学和 国家犹太人健康； Cedar Sinai医疗中心现在包括在此续签中。行政核心 （核心A）该计划将在维持富有成效和充满活力的协作中发挥重要作用，确保 并跟踪遵守NIH以及其他相关法规和准则，并管理将 继续加强围绕该计划的研究社区。行政核心有 以下具体目的：（1）管理日常行政细节和编程需求 AADCRC计划通过提供财政管理，管理分包合同，确保该监管 满足要求，并通过计划目标监视进度； （2）创建一个基础架构 促进项目，核心和核心之间的沟通。调查人员和NIH计划董事以及 如果有必要提供冲突解决方案； （3）协助及时传播研究结果 在本地和全国范围内，科学界的时尚，并向公众提供信息，包括 研究参与者； 4）为AADCRC实施基础设施和机会基金。我们的建议建立 在我们20多年的积极和产品合作中，将大大增强我们的理解 2型炎症与病毒之间相互作用的固有分子机制 哮喘的恶化。我们项目之间的强大协同作用将加速发展的进步 通过证明研究中的先天免疫成分预防病毒的疗法 哮喘感染。